Photo of Michael J. Nathenson,  MD

Michael J. Nathenson, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-5204
Fax: (617) 632-3408


michaelj_nathenson@dfci.harvard.edu

Michael J. Nathenson, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Clinical Instructor, Medicine, Harvard Medical School
  • Clinical Instructor, Soft Tissue and Bone Sarcoma, Dana-Farber Cancer Institute
  • Clinical Instructor, Oncology, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Publications

Powered by Harvard Catalyst
  • Cote GM, Choy E, Chen T, Marino-Enriquez A, Morgan J, Merriam P, Thornton K, Wagner AJ, Nathenson MJ, Demetri G, George S. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. Eur J Cancer 2020; 126:21-32. PubMed
  • Hemming ML, Nathenson MJ, Lin JR, Mei S, Du Z, Malik K, Marino-Enriquez A, Jagannathan JP, Sorger PK, Bertagnolli M, Sicinska E, Demetri GD, Santagata S. Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of . JCO Precis Oncol 2020; 4:79-90. PubMed
  • Ali AMR, Tsai JW, Leung CH, Lin H, Ravi V, Conley AP, Lazar AJ, Wang WL, Nathenson MJ. The immune microenvironment of uterine adenosarcomas. Clin Sarcoma Res 2020; 10:5. PubMed
  • Joseph J, Nathenson MJ, Trinh VA, Malik K, Nowell E, Carter K, Weathers SP, Demetri GD, Araujo D, Conley AP. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor. J Immunother Cancer 2019; 7:296. PubMed
  • Doyle LA, Nowak JA, Nathenson MJ, Thornton K, Wagner AJ, Johnson JM, Albrayak A, George S, Sholl LM. Characteristics of mismatch repair deficiency in sarcomas. Mod Pathol 2019. PubMed
  • Nathenson MJ, Barysauskas CM, Nathenson RA, Regine WF, Hanna N, Sausville E. Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma. World J Surg Oncol 2018; 16:203. PubMed
  • Nathenson MJ, Conley AP, Lin H, Fleming N, Lazar A, Wang WL, Ravi V. The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes. Int J Gynecol Cancer 2018; 28:1297-1310. PubMed
  • Nathenson MJ, Conley A. Prognostic factors for uterine adenosarcoma: a review. Expert Rev Anticancer Ther 2018. PubMed
  • Nathenson MJ, Conley AP, Sausville E. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Oncologist 2018; 23:71-83. PubMed
  • Machida H, Nathenson MJ, Takiuchi T, Adams CL, Garcia-Sayre J, Matsuo K. Significance of lymph node metastasis on survival of women with uterine adenosarcoma. Gynecol Oncol 2018; 144:524-530. PubMed
  • Nathenson MJ, Conley AP, Lin H, Fleming N, Ravi V. Treatment of Recurrent or Metastatic Uterine Adenosarcoma. Sarcoma 2018; 2017:4680273. PubMed
  • Nathenson MJ, Sausville E. Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas. Cancer Chemother Pharmacol 2017; 78:895-919. PubMed
  • Nathenson MJ, Ravi V, Fleming N, Wang WL, Conley A. Uterine Adenosarcoma: a Review. Curr Oncol Rep 2017; 18:68. PubMed
Hide
Member Summary Video